Stream Biomedical

About Stream Biomedical

Stream Biomedical, Inc. is a clinical-stage biopharmaceutical company established in 2016 and headquartered in Houston, Texas. The company focuses on developing neuroreparative therapies to address significant unmet needs for individuals with neurologic trauma or degeneration. It was founded by Gary B. Gage, who now serves as the Chief Operating Officer. The leadership team includes William D. Schwieterman, M.D., who was appointed CEO in October 2020. Dr. Schwieterman brings substantial experience from his time as a supervisor at the Food and Drug Administration (FDA), where he was involved in the approval of numerous biologic drugs, providing a deep background in clinical and regulatory development.

The company's core business revolves around the development of first-in-class targeted therapeutics for conditions like acute ischemic stroke, traumatic brain injury (TBI), Alzheimer's disease, and other neurodegenerative disorders. Stream Biomedical operates in the drug discovery and biotechnology industry, aiming to provide solutions that promote functional recovery after a neurologic insult. Its business model is centered on advancing its therapeutic candidates through preclinical and clinical trials to eventually secure regulatory approval and commercialize its products. The company is privately held and has successfully raised capital to fund its research and development efforts, securing $26.5M in funding from investors including Bios Partners, Johnson & Johnson Innovation - JLABS, and the Denniston Family Office.

Stream Biomedical's lead product candidate is a recombinant therapeutic protein known as Recombinant Human Perlecan Domain V (rhPDV). Specifically, its advanced candidate is rhPDVLG3, a novel biologic agent. This protein has demonstrated neuroprotective and neuroreparative properties in preclinical studies, suggesting it can limit the effects of injury and promote repair. The therapy is designed to be administered after a neurologic event to foster functional improvement. For instance, in experimental stroke models, the treatment has been shown to reduce infarct volume and improve functional outcomes. The company is targeting a range of applications, from acute stroke and TBI to chronic conditions like Alzheimer's, Parkinson's, and vascular dementia, with the goal of revolutionizing neurovascular repair.